Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity

Biochemical Pharmacology

Volumn 79, Issue 2, 2010, Pages 137-146

  Liu, Ling ^b   Yang, Cheng ^b   Herzog, Christian ^b   Seth, Rohit ^b   Kaushal, Gur P ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acute kidney injury; AIF; Apoptosis; Bax; Mcl 1; MG 132; Mitochondria; PS 341

Indexed keywords

APOPTOSIS INDUCING FACTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE; CISPLATIN; CYTOCHROME C; PROTEASOME INHIBITOR; PROTEIN MCL 1; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; IN VIVO STUDY; MALE; MITOCHONDRION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CISPLATIN; IMMUNOPRECIPITATION; KIDNEY; LLC-PK1 CELLS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SWINE;

EID: 71749119515     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.015     Document Type: Article

References (55)

1. Arany I., and Safirstein R.L. Cisplatin nephrotoxicity. Semin Nephrol 23 (2003) 460-464
2. Pabla N., and Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73 (2008) 994-1007
3. Modjtahedi N., Giordanetto F., Madeo F., and Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol 16 (2006) 264-272
4. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
5. Joza N., Susin S.A., Daugas E., Stanford W.L., Cho S.K., Li C.Y., et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410 (2001) 549-554
6. Mate M.J., Ortiz-Lombardia M., Boitel B., Haouz A., Tello D., Susin S.A., et al. The crystal structure of the mouse apoptosis-inducing factor AIF. Nat Struct Biol 9 (2002) 442-446
7. Cande C., Vahsen N., Kouranti I., Schmitt E., Daugas E., Spahr C., et al. AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene 23 (2004) 1514-1521
8. Pospisilik J.A., Knauf C., Joza N., Benit P., Orthofer M., Cani P.D., et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 131 (2007) 476-491
9. Vahsen N., Cande C., Briere J.J., Benit P., Joza N., Larochette N., et al. AIF deficiency compromises oxidative phosphorylation. EMBO J 23 (2004) 4679-4689
10. Buchan A.M., Li H., and Blackburn B. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation. Neuroreport 11 (2000) 427-430
11. Seth R., Yang C., Kaushal V., Shah S.V., and Kaushal G.P. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280 (2005) 31230-31239
12. Cummings B.S., and Schnellmann R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302 (2002) 8-17
13. Yang C., Kaushal V., Shah S.V., and Kaushal G.P. Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am J Physiol Renal Physiol 292 (2007) F1710-F1717
14. Itoh M., Takaoka M., Shibata A., Ohkita M., and Matsumura Y. Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 298 (2001) 501-507
15. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21 (2007) 30-36
16. Desagher S., Osen-Sand A., Nichols A., Eskes R., Montessuit S., Lauper S., et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144 (1999) 891-901
17. Yang C., Kaushal V., Haun R.S., Seth R., Shah S.V., and Kaushal G.P. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ 15 (2008) 530-544
18. Moubarak R.S., Yuste V.J., Artus C., Bouharrour A., Greer P.A., Menissier-de Murcia J., et al. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated programmed necrosis. Mol Cell Biol 27 (2007) 4844-4862
19. Rashmi R., Kumar S., and Karunagaran D. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis 26 (2005) 713-723
20. Whiteman M., Chu S.H., Siau J.L., Rose P., Sabapathy K., Schantz J.T., et al. The pro-inflammatory oxidant hypochlorous acid induces Bax-dependent mitochondrial permeabilisation and cell death through AIF-/EndoG-dependent pathways. Cell Signal 19 (2007) 705-714
21. Brunelle J.K., Shroff E.H., Perlman H., Strasser A., Moraes C.T., Flavell R.A., et al. Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death. Mol Cell Biol 27 (2007) 1222-1235
22. Craig R.W. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16 (2002) 444-454
23. Cuconati A., Mukherjee C., Perez D., and White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 17 (2003) 2922-2932
24. Derouet M., Thomas L., Cross A., Moots R.J., and Edwards S.W. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 279 (2004) 26915-26921
25. Derouet M., Thomas L., Moulding D.A., Akgul C., Cross A., Moots R.J., et al. Sodium salicylate promotes neutrophil apoptosis by stimulating caspase-dependent turnover of Mcl-1. J Immunol 176 (2006) 957-965
26. Inoshita S., Takeda K., Hatai T., Terada Y., Sano M., Hata J., et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 277 (2002) 43730-43734
27. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17 (2003) 1475-1486
28. Piret J.P., Minet E., Cosse J.P., Ninane N., Debacq C., Raes M., et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 280 (2005) 9336-9344
29. Warr M.R., Acoca S., Liu Z., Germain M., Watson M., Blanchette M., et al. BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett 579 (2005) 5603-5608
30. Zhong Q., Gao W., Du F., and Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121 (2005) 1085-1095
31. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
32. Zhuang J., and Brady H.J. Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis. Cell Death Differ 13 (2006) 1263-1267
33. Day C.L., Smits C., Fan F.C., Lee E.F., Fairlie W.D., and Hinds M.G. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol 380 (2008) 958-971
34. Germain M., Milburn J., and Duronio V. MCL-1 inhibits BAX in the absence of MCL-1/BAX Interaction. J Biol Chem 283 (2008) 6384-6392
35. Gillissen B., Essmann F., Hemmati P.G., Richter A., Oztop I., Chinnadurai G., et al. Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol 179 (2007) 701-715
36. Han J., Goldstein L.A., Gastman B.R., and Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281 (2006) 10153-10163
37. Wang X., Chen W., Zeng W., Bai L., Tesfaigzi Y., Belinsky S.A., et al. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7 (2008) 1156-1163
38. Adams K.W., and Cooper G.M. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 282 (2007) 6192-6200
39. Jiang M., Wei Q., Wang J., Du Q., Yu J., Zhang L., et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25 (2006) 4056-4066
40. Nagothu K.K., Bhatt R., Kaushal G.P., and Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 68 (2005) 2680-2693
41. Polster B.M., Basanez G., Etxebarria A., Hardwick J.M., and Nicholls D.G. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 280 (2005) 6447-6454
42. Ruchalski K., Mao H., Li Z., Wang Z., Gillers S., Wang Y., et al. Distinct hsp70 domains mediate apoptosis-inducing factor release and nuclear accumulation. J Biol Chem 281 (2006) 7873-7880
43. Takaoka M., Itoh M., Kohyama S., Shibata A., Ohkita M., and Matsumura Y. Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats. J Cardiovasc Pharmacol 36 (2000) S225-S227
44. Campbell B., Adams J., Shin Y.K., and Lefer A.M. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31 (1999) 467-476
45. Pye J., Ardeshirpour F., McCain A., Bellinger D.A., Merricks E., Adams J., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284 (2003) H919-H926
46. Yao J.H., Li Y.H., Wang Z.Z., Zhang X.S., Wang Y.Z., Yuan J.C., et al. Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion. Clin Exp Pharmacol Physiol 34 (2007) 1102-1108
47. Williams A.J., Dave J.R., and Tortella F.C. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 49 (2006) 106-112
48. Zhang L., Zhang Z.G., Zhang R.L., Lu M., Adams J., Elliott P.J., et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32 (2001) 2926-2931
49. Almond J.B., and Cohen G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16 (2002) 433-443
50. Milano A., Iaffaioli R.V., and Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer 43 (2007) 1125-1133
51. Orlowski R.Z., and Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 (2008) 1649-1657
52. Yunmbam M.K., Li Q.Q., Mimnaugh E.G., Kayastha G.L., Yu J.J., Jones L.N., et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol 19 (2001) 741-748
53. Li C., Li R., Grandis J.R., and Johnson D.E. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 7 (2008) 1647-1655
54. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Dunner Jr. K., Huang P., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65 (2005) 11658-11666
55. Jandial D.D., Farshchi-Heydari S., Larson C.A., Elliott G.I., Wrasidlo W.J., and Howell S.B. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15 (2009) 553-560